Amendments to the claims:

This listing of the claims will replace all prior versions, and listings, of the claims in the application:

Listing of the claims:

1. (Currently Amended) A method of delivering an antigen to a ~~an~~ Class I MHC receptor to induce immunity against the antigen in a subject having a disease associated with the presence of the antigen in the subject, which method comprises:

    a) filling particles with the antigen and ATP resulting in ~~an~~ antigen- and ATP-filled particles (Ag/ATP-filled particles);

    b) coating the Ag/ATP-filled particles of step (a) with a ligand for an antigen presenting cell resulting in a ligand-coated Ag/ATP-filled particles;

    c) incubating the ligand-coated Ag/ATP-filled particles of step (b) with isolated ligand-binding antigen presenting cells (APCs) under conditions permitting the ligand-binding APCs to bind to the ligand-coated Ag/ATP-filled particles and APC phagolysosomes to ingest the ligand-coated Ag/ATP-filled particles to facilitate transfer of the ingested antigen from the phagolysosomes into cytoplasm such that the antigen is delivered to a Class I MHC receptor and is expressed on the surface of the APCs (Ag-APCs); and

    d) administering the antigen presenting cells (Ag-APCs

APCs) of step (c) to a subject having the disease so as induce Class I MHC presentation and elicit cytotoxic T-lymphocytes against the antigen, thereby inducing immunity against the antigen.

2.   (Currently Amended) The method of claim 1, wherein the ~~particle~~ particles are ~~is a~~ type O red blood cell ~~ghost~~ ghosts.

3.   (Currently Amended) The method of claim 1, wherein the ~~particle~~ particles are ~~is a liposome~~ liposomes.

4.   (Original) The method of claim 1, wherein the ligand is selected from the group consisting of an immunoglobulin (IgG), complement component C3b, complement component C3bi, maleic anhydride, an oxidized lipid, a sugar, and a polyanion.

5.   (Currently Amended) The method of claim 1, wherein the antigen presenting cells are ~~cell is~~ selected from the group consisting of a~~ dendritic ~~cell~~ cells, a~~ Langerhans ~~cell~~ cells, a~~ ~~monocyte~~ monocytes, a~~ mononuclear ~~phagocyte~~ phagocytes, a~~ ~~macrophage~~ macrophages, a~~ Kupfer ~~cell~~ cells, a~~ microglial ~~cell~~ cells, a~~n~~ ~~osteoclast~~ osteoclasts, and a~~ bone marrow-derived ~~leukocyte~~ lekocytes.

6.   (Original) The method of claim 1, wherein the antigen is a purified antigen.

7.   (Original) The method of claim 6, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

8.   (Currently Amended) The method of claim 1, wherein the antigen is <u>derived from</u> a crude cell extract.

9.   (Original) The method of claim 8, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

10.   (Original) The method of claim 6, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.

11.   (Original) The method of claim 1 further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

12.   (Original) The method of claim 11, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

13.   (Original) The method of claim 1, wherein the immunity induced is against a bacterial or viral antigen.

14.   (Currently Amended) The method of claim 1, wherein the immunity induced is against <u>an antigen present in</u> a cancerous tumor.

15.   (Currently Amended) The method of claim 1, wherein the ~~disease is~~ <u>subject is afflicted with</u> a bacterial<u>-</u> ~~infection~~ or a viral<u>-mediated</u> ~~infection~~ <u>disease</u>.

16.   (Original) The method of claim 1, wherein the disease is

cancer.

17.   (Currently Amended) A method of delivering an antigen to a
~~an~~ Class I MHC receptor to induce immunity against the
antigen in a subject having a disease associated with the
presence of the antigen in the subject, which method
comprises:

a)   filling particles with the antigen and ATP resulting
in ~~an~~ antigen- and ATP-filled particles (Ag/ATP-filled
particles);

b)   coating the Ag/ATP-filled particles of step (a) with a
ligand for an antigen presenting cell resulting in a
ligand-coated Ag/ATP-filled particles;

c)   incubating the ligand-coated Ag/ATP-filled particles
of step (b) with isolated ligand-binding antigen
presenting cells (APCs) under conditions permitting
the ligand-binding APCs to bind to the ligand-coated
Ag/ATP-filled particles and APC phagolysosomes to
ingest the ligand-coated Ag/ATP-filled particles to
facilitate transfer of the ingested antigen from the
phagolysosomes into cytoplasm such that the antigen is
delivered to a Class I MHC receptor and is expressed
on the surface of the APCs (Ag-APCs);

d)   incubating the Ag-APCs of step (c) with lymphocytes
previously removed from the subject having the
disease; and

e)   administering the incubated lymphocytes of step (d) to
the subject so to induce immunity against the antigen

in the subject.

18.   (Currently Amended) The method of claim 17, wherein the
~~particle~~ particles are ~~is a~~ type O red blood cell ~~ghost~~
ghosts.

19.   (Currently Amended) The method of claim 17, wherein the
~~particle~~ particles are ~~is a liposome~~ liposomes.

20.   (Original) The method of claim 17, wherein the ligand is
selected from the group consisting of an immunoglobulin
(IgG), complement component C3b, complement component C3bi,
maleic anhydride, an oxidized lipid, a sugar, and a
polyanion.

21.   (Currently Amended) The method of claim 17, wherein the
antigen presenting cells are ~~cell is~~ selected from the
group consisting of ~~a~~ dendritic ~~cell~~ cells, ~~a~~ Langerhans
~~cell~~ cells, ~~a monocyte~~ monocytes, ~~a~~ mononuclear ~~phagocyte~~
phagocytes, ~~a macrophage~~ macrophages, ~~a~~ Kupfer ~~cell~~ cells,
~~a~~ microglial ~~cell~~ cells, ~~an osteoclast~~ osteoclasts, and ~~a~~
bone marrow-derived ~~leukocyte~~ leukocytes.

22.   (Original) The method of claim 17, wherein the antigen is a
purified antigen.

23.   (Original) The method of claim 22, wherein the antigen is a
cancer cell antigen, a bacterial antigen or a viral
antigen.

24.   (Currently Amended) The method of claim 17, wherein the
antigen is derived from a crude cell extract.

25.   (Original) The method of claim 24, wherein the antigen is a cancer cell antigen, a bacterial antigen or a viral antigen.

26.   (Original) The method of claim 22, wherein the antigen is selected from the group consisting of a peptide, a carbohydrate, a lipid, a glycoprotein, a glycolipid and a lipoprotein.

27.   (Original) The method of claim 17 further comprising delivering at least one stimulatory cytokine with the antigen to the cytoplasmic matrix of an antigen presenting cell which comprises in step (a) filling the particle with the stimulatory cytokine.

28.   (Original) The method of claim 27, wherein the cytokine is IL-12, G-CSF, IL-4, GM-CSF or interferon gamma.

29.   (Original) The method of claim 17, wherein the immunity induced is against a bacterial or viral antigen.

30.   (Currently Amended) The method of claim 17, wherein the immunity induced is against <u>an antigen present in</u> a cancerous tumor.

31.   (Currently Amended) The method of claim 17, wherein the ~~disease is~~ <u>subject is afflicted with</u> a bacterial<u>-</u> ~~infection~~ or a viral<u>-mediated</u> ~~infection~~ <u>disease</u>.

32.   (Original) The method of claim 17, wherein the disease is cancer.

33-132 (Canceled)